Plain-English translation of NCT05950165 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new medication called , designed to treat non-Hodgkin's lymphoma that has come back or no longer responds to standard treatments. The trial has two parts: first, researchers will find the safest and most effective dose of the medication alone, and then test it combined with another drug called . Participants will receive weekly infusions at first, then less frequently over several weeks of treatment.
Many people with non-Hodgkin's lymphoma find that their cancer returns or becomes resistant to available treatments, leaving them with few good options. This medication represents a new approach that may help people whose lymphoma is difficult to control.
You likely qualify if…
You likely don't qualify if…
During the first cycle of treatment, you will come in once per week for 4 weeks to receive an intravenous infusion of the medication. After that, you will return once every 3 weeks for a single infusion. The study will continue for up to 6 cycles (about 19 weeks total), or until your cancer progresses. You will have regular blood tests and scans to monitor how well the treatment is working and to watch for any side effects.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
Taiwan